Entering text into the input field will update the search result below

Flexion's FX006 Fast Track'd for osteoarthritis of the knee

Sep. 01, 2015 4:18 PM ETPacira BioSciences, Inc. (PCRX) StockPCRXBy: Douglas W. House, SA News Editor1 Comment
  • The FDA grants Fast Track status to Flexion Therapeutics' (NASDAQ:FLXN) lead product candidate, FX006, for the treatment of patients with osteoarthritis of the knee, a condition affecting over 4M Americans.
  • Fast Track status provides for more interactions with the FDA review team and a rolling review of the New Drug Application (NDA).
  • FX006 is a novel, non-opioid, sustained release, intra-articular formulation of triamcinolone acetonide, a corticosteroid used to treat a variety of inflammatory conditions. Data from a Phase 3 study are expected in Q1 2016.

Recommended For You

About PCRX Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
PCRX--
Pacira BioSciences, Inc.